MedWatch

Zealand boss must outperform Novo and Eli Lilly: "I'm not worried"

If Zealand Pharma gets its emergency treatment against low blood sugar approved by the FDA as expected, the company will face tough competition, but CEO Emmanuel Dulac believes he has the best product and is ready to prove it in trials.

Emmanuel Dulac, CEO of Zealand Pharma, is not scared of the competition from Novo Nordisk, Eli Lilly and Xeris. Photo: Zealand Pharma / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles